Current status and problems in preclinical assessment of immunomodulators.
Masek
K
K
Institute of Pharmacology, Czechoslovak Academy of Sciences, Prague.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology; D000276:Adjuvants, Immunologic / Q000592:standards* / Q000627:therapeutic use / Q000633:toxicity; D000547:Amantadine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D004261:DNA Replication / Q000187:drug effects; D004151:Dipeptides / Q000494:pharmacology; D004306:Dose-Response Relationship, Immunologic; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000592:standards; D006087:Graft vs Host Reaction / Q000187:drug effects; D007167:Immunotherapy; D007249:Inflammation / Q000139:chemically induced; D051379:Mice; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013329:Structure-Activity Relationship; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors
D000276:Adjuvants, Immunologic; D004151:Dipeptides; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C044891:adamantylamide-alanyl-isoglutamine; D000547:Amantadine; D013937:Thymidine Kinase